Roszet is a drug owned by Althera Pharmaceuticals Llc. It is protected by 2 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2033. Details of Roszet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10376470 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(8 years from now) | Active |
| US9763885 | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Roszet's patents.
Latest Legal Activities on Roszet's Patents
Given below is the list of recent legal activities going on the following patents of Roszet.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Feb, 2023 | US10376470 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Oct, 2021 | US9763885 |
| Email Notification Critical | 08 Oct, 2021 | US9763885 |
| Change in Power of Attorney (May Include Associate POA) Critical | 08 Oct, 2021 | US10376470 |
| Email Notification Critical | 08 Oct, 2021 | US10376470 |
| Correspondence Address Change Critical | 06 Oct, 2021 | US10376470 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 23 Nov, 2020 | US9763885 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Aug, 2019 | US10376470 |
| Recordation of Patent Grant Mailed Critical | 13 Aug, 2019 | US10376470 |
| Email Notification Critical | 25 Jul, 2019 | US10376470 |
US patents provide insights into the exclusivity only within the United States, but Roszet is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Roszet's family patents as well as insights into ongoing legal events on those patents.
Roszet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Roszet's generic launch date based on the expiry of its last outstanding patent is estimated to be May 01, 2033 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Roszet Generics:
There are no approved generic versions for Roszet as of now.
About Roszet
Roszet is a drug owned by Althera Pharmaceuticals Llc. It is used for lowering high levels of lipids in the blood. Roszet uses Ezetimibe; Rosuvastatin Calcium as an active ingredient. Roszet was launched by Althera Pharms in 2021.
Approval Date:
Roszet was approved by FDA for market use on 23 March, 2021.
Active Ingredient:
Roszet uses Ezetimibe; Rosuvastatin Calcium as the active ingredient. Check out other Drugs and Companies using Ezetimibe; Rosuvastatin Calcium ingredient
Treatment:
Roszet is used for lowering high levels of lipids in the blood.
Dosage:
Roszet is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG;EQ 5MG BASE | TABLET | Discontinued | ORAL |
| 10MG;EQ 10MG BASE | TABLET | Discontinued | ORAL |
| 10MG;EQ 20MG BASE | TABLET | Discontinued | ORAL |
| 10MG;EQ 40MG BASE | TABLET | Discontinued | ORAL |